GlobalAccess Health – Funding the Next Million Diagnoses

1. Most tests are delivered through highly subsidised channels.

• Total tests = 17m; government clinics (7m) and humanitarian campaigns (3m) together account for the majority of volume, with NGOs adding another 5m.
• Humanitarian campaigns are 100% free, and government clinics still have a large free component.
• A large share of GAH’s impact is in channels with little or no direct revenue.

2. Revenue is concentrated in a few segments, especially NGOs and private labs.

• Paying volume is 10m tests: 4m government, 4m NGO, 2m private labs.
• Approximate revenue: government $2m, NGOs $4m, private labs $4m; total ≈ $10m.
• NGOs and private labs generate 80% of revenue while representing only about a third of total tests.

3. Cross-subsidy potential and equity trade-offs are explicit.

• Private labs operate mainly in higher-income markets but generate the highest revenue per test.
• Government and humanitarian channels serve almost exclusively low-income countries at low or zero prices.
• Suggests a cross-subsidy model: higher-price, lower-equity segments support ultra-low-price, high-equity segments.

4. Implications for strategy.

• Significant headroom to grow revenue from NGOs and private labs without changing prices in the poorest public and humanitarian channels.
• Price changes in government clinics are politically and ethically sensitive.

Strong candidates translate these insights into a hypothesis, e.g., focusing on growing and re-pricing NGO and private-lab segments while protecting public and humanitarian access.

1. Channel and product strategy

• Aggressively grow high-revenue segments (private labs, middle-income NGOs) with tiered offerings and value-added services.
• Protect or expand ultra-low-price/free segments (government clinics, humanitarian campaigns) funded by cross-subsidy and grants.
• Explore adjacent revenue streams that also support impact (e.g., paid training services, data analytics).

2. Refined tiered pricing and cross-subsidy model

• Design transparent tiered pricing by country income level, partner type, and volume.
• Set explicit cross-subsidy rules (e.g., each private-lab contract contributes to an access fund).
• Use long-term contracts to stabilise revenue.

3. Cost and efficiency improvements

• Reduce logistics and overhead cost per test through optimisation and shared services.
• Invest in digital tools to reduce waste and stock-outs.
• Prioritise high-impact, high-efficiency programmes when expanding.

4. Partnerships and innovative financing

• Create blended-finance mechanisms where donors match revenue from paying partners.
• Partner with governments or multilaterals for multi-year contracts that blend budget support with performance-based top-ups.

5. Governance and safeguards

• Establish a clear policy protecting humanitarian and low-income public channels.
• Introduce equity audits and public reporting on coverage by income level and geography.

1. Restate the objective
   - GAH wants to know whether and how to pursue an aggressive earned-income strategy to reach at least 60% cost recovery in 5 years while maintaining equitable access.

2. Core recommendation
   - Recommend a selectively aggressive earned-income strategy focused on:
     • Expanding and re-pricing higher-ability-to-pay segments (NGOs and private labs), and
     • Explicitly protecting free or ultra-low-price access in government and humanitarian channels through a formal cross-subsidy model.

3. Key supporting arguments
   - Channel analysis: Most tests are delivered through low-/no-price channels, while most revenue comes from NGOs and private labs, indicating clear scope to grow income without charging the poorest users.
   - Quantitative feasibility: A scenario with higher prices and 50% volume growth in private labs can move cost recovery from 40% to 60% without increasing prices for government clinics or NGOs.
   - Strategic fit: A channel-specific, tiered pricing model aligns with GAH’s mission if coupled with clear access guardrails.

4. Risks and mitigations
   - Demand and reputational risk in private-lab markets if prices rise too sharply → test willingness to pay via pilots; phase in price increases; offer value-added services.
   - Mission drift if revenue targets dominate → codify access principles, implement equity metrics, and ensure board oversight.
   - Operational risk in scaling higher-margin segments → invest in commercial capabilities and maintain core programme capacity.

5. Suggested next steps
   - Quantify channel-level scenarios to confirm feasibility under different assumptions.
   - Co-design a tiered pricing and cross-subsidy policy with donors and key partners, including explicit protection for humanitarian and low-income public channels.
   - Develop an implementation roadmap for capability building, governance changes, and pilots before scaling.